FDA criticized for Alzheimer's drug approval process

New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The report said the FDA worked too closely with Biogen despite significant concerns over the limited benefits and side effects of the new drug, Aduhelm. Geoff Bennett reports.